Table 1.
The inhibitory effects of seventeen constituents in ERC against hPL-catalyzed 4-methylumbelliferyl oleate (4-MUO) hydrolysis.
| No. | Compound | Molecular weight | pIC50 |
|---|---|---|---|
| 1 | Epicatechin | 290.27 | <4 |
| 2 | p-coumaric acid | 164.16 | <4 |
| 3 | Ferulic acid | 194.18 | <4 |
| 4 | Epicatechin gallate | 442.37 | 6.79 ± 0.02 |
| 5 | Catechin gallate | 442.37 | 7.68 ± 0.23 |
| 6 | 1,2,3,4,6-penta-O-galloyl-β-d-glucopyranose (PGG) | 940.68 | 7.59 ± 0.03 |
| 7 | Luteolin-7-O-β-d-glucoside | 448.38 | <4 |
| 8 | Afzelin | 432.38 | <4 |
| 9 | Quercetin-3-O-glucoside | 464.38 | <4 |
| 10 | Rhodiosin | 610.52 | <4 |
| 11 | Quercetin-3-O-glucuronide | 478.36 | <4 |
| 12 | Rhodionin | 448.38 | <4 |
| 13 | Quercitrin | 448.38 | <4 |
| 14 | Eriodictyol | 288.25 | <4 |
| 15 | Quercetin | 302.24 | 6.42 ± 0.13 |
| 16 | Luteolin | 286.24 | 6.11 ± 0.06 |
| 17 | Kaempferol | 286.24 | 4.56 ± 0.03 |
| Positive inhibitor | Orlistat a | 495.74 | 7.98 ± 0.02 |
a
Orlistat (a marketed hPL inhibitor) was used as the positive hPL inhibitor.